3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow Solid Cancers: new trials by email Literature Review of Solid Cancers trials Research Report on Solid Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer | Phase 1 | Terminated | Exelixis | 9 | 2024-10-17 | 2025-06-25 |
| A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer Fulvestrant, GDC-0032, Letrozole - Solid Cancers, Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Genentech, Inc. | 674 | 2011-03-16 | 2024-07-31 |
| A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies GDC-0152 - Solid Cancers | Phase 1 | Terminated | Genentech, Inc. | 40 | 2007-06-01 | 2017-06-21 |
Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Male Urogenital Diseases (1)
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · Fulvestrant (1) · GDC-0152 (1) · Letrozole (1) · Midazolam (1)
Genentech, Inc. (2) · Exelixis (1)
United States (2) · Canada (1) · France (1) · Spain (1)